Clinical Trials Logo

Coronavirus Infection clinical trials

View clinical trials related to Coronavirus Infection.

Filter by:

NCT ID: NCT04445454 Recruiting - Clinical trials for Coronavirus Infection

Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection

Start date: June 12, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The overall objective of the study is to evaluate the safety and efficacy of MSC therapy combined with best supportive care in hospitalized patients with COVID-19.

NCT ID: NCT04445441 Completed - Clinical trials for Coronavirus Infection

An Observational Study to Assess the Protocol for the COVID-19 Treatment in Burkina Faso

CHLORAZ
Start date: April 24, 2020
Phase:
Study type: Observational

This is an observational study to evaluate the effectiveness of the combinations Hydroxychloroquine + Azithromycin (HCQ-AZ) and Chloroquine + Azithromycin (CQ-AZ) in the treatment of Coronavirus (Covid-19) infection in Burkina Faso.

NCT ID: NCT04444700 Completed - COVID Clinical Trials

A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic

RAPID-BRAZIL
Start date: July 4, 2020
Phase: Phase 3
Study type: Interventional

Coagulopathy of COVID-19 afflicts approximately 20% of patients with severe COVID-19 and is associated with need for critical care and death. COVID-19 coagulopathy is characterized by elevated D-dimer, an indicator of fibrin formation and clot lysis, and a mildly prolonged prothrombin time, suggestive of coagulation consumption. To date, it seems that COVID-19 coagulopathy manifests with thromboembolism, thus anticoagulation may be of benefit. We propose to conduct a parallel pragmatic multi-centre open-label randomized controlled trial to determine the effect of therapeutic anticoagulation compared to standard care in hospitalized patients admitted for COVID-19 with an elevated D-dimer.

NCT ID: NCT04442230 Terminated - Clinical trials for Coronavirus Infection

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

Start date: October 10, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of NasoVAX in preventing worsening of symptoms and hospitalization in patients with early COVID-19.

NCT ID: NCT04431466 Terminated - Clinical trials for Coronavirus Infection

A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19

IFORS
Start date: July 1, 2020
Phase: Phase 2
Study type: Interventional

In December 2019, a group of patients with pneumonia of unknown cause was linked to a wholesale seafood market in Wuhan, China. The genetic analysis of samples from the lower respiratory tract of these patients indicated a new coronavirus as the causative agent, which was named SARS-CoV-2. The virus spread rapidly to more than 45 countries, including Brazil, causing an international alarm. However, in spite of its epidemiological magnitude, so far, there is no antiviral treatment or vaccine approved for the treatment of this infection. With about 15% to 20% of SARS-CoV-2 patients suffering from serious illnesses and overburdened hospitals, therapeutic options are desperately needed. So, instead of creating compounds from scratch that can take years to develop and test, researchers and public health agencies have sought to redirect drugs already approved for other diseases and known to be widely safe. In this context, the analysis of the international literature shows the existence of an in vitro antiviral activity of ivermectin against SARS-CoV-2. However, there are no studies that have evaluated its clinical effectiveness in patients diagnosed with SARS-CoV-2 infection. Therefore, and considering this knowledge gap, the present study aims to determine the clinical efficacy and safety of different doses of ivermectin in patients diagnosed with SARS-CoV-2 infection.

NCT ID: NCT04427969 Completed - Clinical trials for Acute Respiratory Failure

Early Prone Position on Coronavirus Disease 2019 Pneumonia

Prone Position
Start date: June 15, 2020
Phase:
Study type: Observational

the purpose of this study to evaluate the effect of early awake PP (prone position)application on oxygenation and intubation requirement in patients with acute respiratory failure due to coronavirus disease 2019 pneumonia.

NCT ID: NCT04427280 Completed - Cancer Clinical Trials

Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19)

CARDS
Start date: May 26, 2020
Phase:
Study type: Observational

People with cancer may be at higher risk of poor outcomes with COVID-19 infection. This observational study aims to describe the clinical course of COVID-19 infection in people with cancer and evaluate the utility of antibody and antigen tests for COVID-19. The results of this study will inform clinical practice in the management of cancer patients with COVID-19.

NCT ID: NCT04424953 Completed - Clinical trials for Coronavirus Infection

To Compare Videolaryngoscope Against Direct Laryngoscope for Intubation When Powered Air Purifying Respirator is Worn

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

Various guidelines for endotracheal intubation (insertion of breathing tube for mechanical ventilation) of Coronavirus Disease 2019 (COVID-19) patients recommend the use of videolaryngoscope (medical device used for intubation that has a camera to visualize the vocal cords between which the breathing tube will pass) over direct laryngoscope (conventionally-used medical device for intubation that depends on anesthetist's direct visualization of vocal cords). The reasons for this recommendation are to maximize the distance between the medical personnel and the patient's face during intubation to decrease the risk of viral particles transmission and to improve intubation success. For patients infected with COVID-19, Powered Air Purifying Respirator (PAPR) is recommended as an alternative to N95 masks during aerosol-generating procedures such as intubation because N95 masks may not fully protect medical personnel from viral transmission during intubation. There is no evidence to suggest that videolaryngoscope (VL) is superior to direct laryngoscope (DL) for intubation when PAPR is donned. The purpose of this study is to determine if McGrath VL is superior to DL for intubation when the anesthetist is wearing a PAPR. The investigators' hypothesis is that McGrath VL will decrease the time to intubation by 20 seconds and more compared to DL when PAPR is donned. The investigators also hope to learn if there is any difference in the difficulties encountered between the use of VL and DL.

NCT ID: NCT04424836 Completed - Clinical trials for Acute Respiratory Failure

HFNC Treatment in COVID-19 Pneumonia

Start date: May 15, 2020
Phase:
Study type: Observational

coronavirus disease 2019 related pneumonia is causing acute respiratory failure and this is the most common reason for ICU admission. We have several different way for respiratory support. HFNC is one of the new technics for oxygen support. Our main purpose to observe the effect of HFNC on coronavirus disease 2019 patients' ICU stay and mortality.

NCT ID: NCT04422535 Recruiting - Clinical trials for Coronavirus Infection

Effects on the Qt Interval of COVID-19 Coronavirus Infection

QT-COVID-19
Start date: May 29, 2020
Phase:
Study type: Observational

The present study aims to evaluate the impact of COVID-19 disease and its treatment on ventricular repolarization, assessed by measuring the QTc interval, in patients admitted to the critical care unit.